Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years

Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years

Health Canada approved pembrolizumab in the first-line setting for advanced non-small-cell lung cancer with PD-L1 ≥ 50% and no EGFR/ALK aberration. The keynote 024 trial showed 55% of such patients progress with pembrolizumab monotherapy. We propose that the combination of baseline CT and clinical f...

Full description

Bibliographic Details
Main Authors: Ali Silver, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara Melosky, Ren Yuan
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Current Oncology
Subjects:
non-small-cell lung cancer
baseline CT
smoking pack years
pembrolizumab
tumor response
survival
Online Access:https://www.mdpi.com/1718-7729/30/6/419

Internet

https://www.mdpi.com/1718-7729/30/6/419

Similar Items